Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Changes To Generic Drug Bioequivalence Requirements Could Mean Higher Study Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee agrees with the Office of Generic Drugs that bioequivalence standards should be tighter for generic versions of "critical dose" or "narrow therapeutic index" drugs.

You may also be interested in...



Bioequivalence Margins Do Not Need Revision For All Generics, Panel Says

While narrower bioequivalence margins might be necessary for certain categories of generic drugs, FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee has determined that the specifications should not be tightened across the board for all generic drug approvals

Bioequivalence Margins Do Not Need Revision For All Generics, Panel Says

While narrower bioequivalence margins might be necessary for certain categories of generic drugs, FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee has determined that the specifications should not be tightened across the board for all generic drug approvals

Committee Rejects FDA Proposal To Narrow Bioequivalence Margins

The Pharmaceutical Science and Clinical Pharmacology Advisory Committee doesn't see the additional criteria as necessary, but FDA could still impose narrower bioequivalence margins over its objections.

Related Content

Topics

UsernamePublicRestriction

Register

PS070478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel